{"id":233893,"date":"2017-08-10T13:40:13","date_gmt":"2017-08-10T17:40:13","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/head-to-head-analysis-photomedex-phmd-vs-edap-tms-edap-week-herald.php"},"modified":"2017-08-10T13:40:13","modified_gmt":"2017-08-10T17:40:13","slug":"head-to-head-analysis-photomedex-phmd-vs-edap-tms-edap-week-herald","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/tms\/head-to-head-analysis-photomedex-phmd-vs-edap-tms-edap-week-herald.php","title":{"rendered":"Head-To-Head Analysis: PhotoMedex (PHMD) vs. EDAP TMS (EDAP) &#8211; Week Herald"},"content":{"rendered":"<p><p>    EDAP TMS (NASDAQ: EDAP) and PhotoMedex (NASDAQ:PHMD) are both    small-cap medical companies, but which is the superior    business? We will compare the two companies based on the    strength of their analyst recommendations, valuation,    dividends, institutional ownership, profitabiliy, earnings and    risk.  <\/p>\n<p>    Institutional and Insider Ownership  <\/p>\n<p>    8.2% of EDAP TMS shares are owned by institutional investors.    Comparatively, 5.2% of PhotoMedex shares are owned by    institutional investors. 22.4% of PhotoMedex shares are owned    by company insiders. Strong institutional ownership is an    indication that large money managers, endowments and hedge    funds believe a company is poised for long-term growth.  <\/p>\n<p>    Analyst Recommendations  <\/p>\n<p>    This is a breakdown of current ratings and recommmendations for    EDAP TMS and PhotoMedex, as reported by MarketBeat.com.  <\/p>\n<p>    EDAP TMS currently has a consensus target price of $7.00,    indicating a potential upside of 149.11%. Given EDAP TMSs    higher probable upside, research analysts clearly believe EDAP    TMS is more favorable than PhotoMedex.  <\/p>\n<p>    Earnings & Valuation  <\/p>\n<p>    This table compares EDAP TMS and PhotoMedexs top-line revenue,    earnings per share and valuation.  <\/p>\n<p>    EDAP TMS has higher revenue and earnings than PhotoMedex.  <\/p>\n<p>    Profitability  <\/p>\n<p>    This table compares EDAP TMS and PhotoMedexs net margins,    return on equity and return on assets.  <\/p>\n<p>    Volatility & Risk  <\/p>\n<p>    EDAP TMS has a beta of 0.98, suggesting that its stock price is    2% less volatile than the S&P 500. Comparatively,    PhotoMedex has a beta of 0.74, suggesting that its stock price    is 26% less volatile than the S&P 500.  <\/p>\n<p>    Summary  <\/p>\n<p>    EDAP TMS beats PhotoMedex on 10 of the 11 factors compared    between the two stocks.  <\/p>\n<p>    About EDAP TMS  <\/p>\n<p>    EDAP TMS S.A. (EDAP) is a holding company engaged    in developing and marketing the Ablatherm and Focal One    devices. The Company operates two divisions: High Intensity    Focused Ultrasound (HIFU) and Urology Devices and Services    (UDS) (including lithotripsy activities). The Company is    developing HIFU technology for the treatment of certain other    types of tumors. The Company also produces and commercializes    medical equipment for treatment of urinary tract stones using    extra-corporeal shockwave lithotripsy (ESWL) and distributes    other types of urology devices in certain countries. The HIFU    division is engaged in the development, manufacturing and    marketing of medical devices based on HIFU technology for the    invasive treatment of urological and other clinical    indications. The UDS division is engaged in the development,    marketing, manufacturing and servicing of medical devices for    the invasive diagnosis or treatment of urological disorders,    urinary stones, and other clinical indications.  <\/p>\n<p>    About PhotoMedex  <\/p>\n<p>    PhotoMedex, Inc. is a global health products and    services company providing integrated disease management and    solutions to dermatologists, professional aestheticians and    consumers. The Company provides products and services that    address skin diseases and conditions, including acne and photo    damage. The Company operates through three business segments:    Consumer segment, Physician Recurring segment and Professional    segment. The Company provides skin health solutions to spa    markets, as well as traditional retail, online and infomercial    outlets for home-use products. The Companys Consumer segment    is engaged in the designing, development, manufacturing and    selling of long-term hair reduction and acne consumer products.    Its Physician Recurring segment is engaged in the sales of    skincare products. Its Professional segment is engaged in the    sale of equipment, such as medical and esthetic light and heat    based products. Its LHE brands includes Mistral, Kona, FSD,    SpaTouch Elite and accessories.   <\/p>\n<p>    Receive News & Ratings for EDAP TMS S.A.    Daily - Enter your email address below to receive a    concise daily summary of the latest news and analysts' ratings    for EDAP TMS S.A. and related companies with     MarketBeat.com's FREE daily email newsletter.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read this article: <\/p>\n<p><a target=\"_blank\" rel=\"nofollow\" href=\"https:\/\/weekherald.com\/2017\/08\/10\/head-to-head-review-edap-tms-edap-vs-photomedex-phmd-updated.html\" title=\"Head-To-Head Analysis: PhotoMedex (PHMD) vs. EDAP TMS (EDAP) - Week Herald\">Head-To-Head Analysis: PhotoMedex (PHMD) vs. EDAP TMS (EDAP) - Week Herald<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> EDAP TMS (NASDAQ: EDAP) and PhotoMedex (NASDAQ:PHMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitabiliy, earnings and risk.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/tms\/head-to-head-analysis-photomedex-phmd-vs-edap-tms-edap-week-herald.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[431603],"tags":[],"class_list":["post-233893","post","type-post","status-publish","format-standard","hentry","category-tms"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/233893"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=233893"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/233893\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=233893"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=233893"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=233893"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}